Equities Analysts Offer Predictions for IOVA Q1 Earnings

Key Points

• HC Wainwright cut its Q1 2026 EPS estimate for Iovance to ($0.22) from ($0.15) and now projects FY2026 EPS of ($0.77) and FY2027 EPS of ($0.57).
• Analyst coverage is mixed — 6 Buys, 4 Holds and 2 Sells — with an average rating of Hold and an average price target of $8.88.
• Iovance recently reported quarterly EPS of ($0.18) and revenue of $86.77M, beating estimates; the stock trades near $3.48 with a $1.43B market cap and a 52‑week range of $1.64–$5.63.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Investment analysts at HC Wainwright cut their Q1 2026 EPS estimates for Iovance Biotherapeutics in a report issued on Wednesday, April 22nd. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will earn ($0.22) per share for the quarter, down from their previous estimate of ($0.15). The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics' Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.77) EPS and FY2027 earnings at ($0.57) EPS.

IOVA has been the topic of several other research reports. Chardan Capital reaffirmed a "buy" rating and issued a $16.00 price target on shares of Iovance Biotherapeutics in a report on Friday, April 10th. Truist Financial raised shares of Iovance Biotherapeutics to a "hold" rating in a report on Wednesday, March 25th. The Goldman Sachs Group reaffirmed a "sell" rating and issued a $2.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. UBS Group upped their price target on shares of Iovance Biotherapeutics from $2.00 to $4.00 and gave the stock a "neutral" rating in a report on Thursday, March 5th. Finally, Citizens Jmp raised shares of Iovance Biotherapeutics from a "market perform" rating to a "market outperform" rating and set a $5.00 price target on the stock in a report on Tuesday, March 3rd. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $8.88.

Iovance Biotherapeutics Stock Performance

Iovance Biotherapeutics stock opened at $3.48 on Friday. The stock has a market cap of $1.43 billion, a P/E ratio of -3.11 and a beta of 0.76. Iovance Biotherapeutics has a fifty-two week low of $1.64 and a fifty-two week high of $5.63. The firm's fifty day moving average price is $3.70 and its 200-day moving average price is $2.85.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.04. The firm had revenue of $86.77 million for the quarter, compared to analysts' expectations of $81.61 million. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%.

Institutional Trading of Iovance Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in IOVA. Vontobel Holding Ltd. purchased a new stake in Iovance Biotherapeutics during the third quarter valued at about $26,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Iovance Biotherapeutics during the third quarter valued at about $27,000. Arcataur Capital Management LLC purchased a new stake in Iovance Biotherapeutics during the fourth quarter valued at about $29,000. Granite Investment Partners LLC purchased a new stake in Iovance Biotherapeutics during the fourth quarter valued at about $29,000. Finally, Motley Fool Asset Management LLC purchased a new stake in Iovance Biotherapeutics during the fourth quarter valued at about $29,000. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company's lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance's pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance's TIL platform harnesses a patient's own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.